Form 4: Bolt Biotherapeutics Director Acquires Stock Options

Nicole Onetto, a Director at Bolt Biotherapeutics, Inc., acquired 5,000 stock options with an exercise price of $4.43.

Summary

• Nicole Onetto, a Director at Bolt Biotherapeutics, Inc. (BOLT), acquired 5,000 stock options on June 10, 2026.
• The stock options have an exercise price of $4.43 per share.
• These options are exercisable and expire on June 9, 2036.
• The underlying securities are 5,000 shares of Common Stock.
• The options are held directly by Ms. Onetto.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction of stock options rather than significant financial results or strategic shifts.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price indicates a potential for future value creation if the stock price appreciates.
• The vesting schedule is tied to continuous service and a change in control, aligning the director's incentives with long-term company performance and shareholder value.

Negatives

• The filing only reports the acquisition of options, not the actual purchase of shares, so there is no immediate cash outlay or increase in beneficial ownership of common stock.
• The exercise price of $4.43 suggests the current market price may be at or below this level, or that the options were granted as part of a compensation package.

Risks

• The vesting of options is contingent on continuous service, meaning departure from the company before vesting could result in forfeiture.
• The value of the options is directly tied to the future performance of Bolt Biotherapeutics' stock price, which is subject to market volatility and company-specific risks.
• A change in control of the issuer would trigger full vesting, which could occur under various circumstances, some of which might not be favorable to all shareholders.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a transaction related to stock options.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to attract and retain talent and align executive interests with long-term company growth, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of confidence, but it does not immediately impact share count or voting power. The ultimate impact depends on future stock performance.
• Employees: The vesting conditions tied to continuous service reinforce the importance of employee retention for the company's operational continuity.
• Management: The option grant aligns management's incentives with long-term shareholder value creation.

Next Steps

• The options will vest on the earlier of June 9, 2027, or the day immediately prior to the next annual meeting of stockholders, subject to continuous service.
• The option will vest in full upon a change in control of the Issuer.

Key Dates

Keywords

Bolt Biotherapeutics, BOLT, Form 4, Stock Options, Insider Trading, Director, Nicole Onetto, Beneficial Ownership, SEC Filing